Amber Bio
Basem Al-Shayeb, Ph.D. has a background in Genetics, Cell Biology, and Development, as well as Microbiology. Basem is currently the Co-Founder and Chief Technology Officer at Amber Bio. Prior to this, Basem was a Ph.D. Candidate & NSF Research Fellow at the University of California, Berkeley, where Basem conducted rotations in various labs including those of Adam Arkin, Jill Banfield, and Jennifer Doudna. Basem also has experience as a Research Associate in Space Life Sciences at NASA Ames Research Center and as a BTI Research Fellow and iGEM Team Lead at BioTechnology Institute.
This person is not in any teams
This person is not in any offices
Amber Bio
2 followers
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.